drugs

OVERAL ® Roxithromycin

OVERAL ® is a drug based on Roxithromycin

THERAPEUTIC GROUP: Antibacterials - antibacterials for systemic use, macrolides

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions OVERAL © Roxithromycin

OVERAL © is indicated in the treatment of infections sustained by microorganisms sensitive to macrolides and responsible for odontostomatological, genital, cutaneous and respiratory diseases.

This antibiotic has also been shown to be effective in the prophylaxis of meningococcal meningitis in individuals at risk.

Mechanism of action OVERAL © Roxithromycin

OVERAL © is an antibiotic based on roxithromycin, an active ingredient belonging to the class of macrolides with 14 carbon atoms.

Although structurally derived from erythromycin, with which it shares the same mechanism of action, characterized by the inhibition of protein synthesis by binding to the 50S ribosomal subunit, useful for providing the site of interaction with the peptidylaminotransferase, an enzyme deputed to the elongation of nascent peptide chain, roxithromycin present different pharmacokinetic characteristics.

In fact, the greater stability in an acid environment allows this active ingredient to be absorbed more quickly from the gastrointestinal tract, appearing in the circulation already after 15 minutes and reaching the maximum plasma concentrations generally around 120 minutes.

Linked to plasma proteins, this macrolide reaches the various tissues, concentrating mainly at the pulmonary level, and carrying out its therapeutic action for several hours, at the end of which, partly unchanged in part in the form of inactive catabolites, is partly eliminated both with I did that with urine.

Studies carried out and clinical efficacy

1 ROXYTHROMYCIN IN THE TREATMENT OF CHRONIC SINUSITIS

Experimental study that demonstrates how low doses of roxithromycin can have a long-term curative effect for chronic sinusitis, improving both the clinical course and the anatomic-pathological characteristics.

2 . THE POSSIBLE ANTI-INFLAMMATORY ROLE OF ROXITROMYCIN

Interesting experimental study that seeks to clarify the molecular mechanisms of action of roxithromycin in asthmatic pathology.

In these examples an attenuation of the inflammation of the respiratory tract was observed in experimental models of asthma, through the modulation of the inflammatory pathway supported by NF-KB.

3. ADVERSE REACTIONS TO ROXITROMYCIN

Interesting case report that reveals the appearance of a serious toxic reaction to the drug roxithromycin, in a 54-year-old patient with upper respiratory tract infection, in which the intake of this drug led to the appearance of severe epidermal necrosis.

Method of use and dosage

OVERAL ©

150 mg coated tablets of roxithromycin;

300 mg coated tablets of roxithromycin;

50 mg dispersible tablets of roxithromycin.

Note the half-life of roxithromycin in adults it is recommended to take one 150 mg tablet twice a day, or one 300 mg once a day.

In pediatric patients the dosage should be defined by your pediatrician based on the severity of the clinical picture.

It is recommended to take OVERAL © before meals due to the delayed systemic absorption induced by the presence of food in the gastrointestinal tract.

Warnings OVERAL © Roxithromycin

OVERAL © should be taken with particular caution in patients suffering from liver and kidney diseases, in which a significant lengthening of the half-life of the drug could occur with possible serious side effects.

The same caution should be reserved for patients with cardiovascular diseases or on therapy with antiarrhythmic drugs, given the ability of roxithromycin to lengthen the QT interval.

OVERAL © contains glucose, therefore its use should be limited in patients with diabetes or glucose / galactose malabsorption syndrome.

PREGNANCY AND BREASTFEEDING

Given the absence of data that can characterize the safety profile of roxithromycin on the fetus, the use of this drug during pregnancy is not recommended.

This contraindication should also be extended to the subsequent breastfeeding period, note the ability of the active ingredient to be minimally excreted even with breast milk.

Interactions

In order to avoid the occurrence of serious and unpredictable adverse reactions, the simultaneous intake of roxithromycin is not recommended and:

  • Ergotamine and vasoconstrictor alkaloids, responsible in some cases for necrosis of the extremities;
  • Active ingredients with cardiac effect such as astemizole, cisapride, pimozide and terfenadine;
  • Active ingredients metabolized by the cytochrome enzyme class.

It is therefore advisable to always consult your doctor in these cases.

Contraindications OVERAL © Roxithromycin

OVERAL © is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients, severe hepatic failure or contextual therapy with ergotamine or alkaloids with marked vasoconstrictive activity.

Undesirable effects - Side effects

Taking OVERAL © even at therapeutic doses could expose the patient to different adverse reactions, some of which are characterized by a severe clinical course.

Gastrointestinal reactions such as nausea, vomiting, diarrhea, dyspepsia, respiratory diseases, erythema, rash, urticaria and angioedema, headache and dizziness are fortunately the most frequently observed and characterized by a time course limited to the period of intake of the drug.

Alterations in the immunological picture, superinfections with resistant microorganisms and adverse reactions in the liver, are the result of clinically more relevant therapy with OVERAL ©.

Note

OVERAL © is a prescription drug subject to mandatory medical treatment.